Provectus Pharmaceuticals Announces Financial Results for Year End 2007
|
|
KNOXVILLE, Tennessee, March 31, 2008 (BUSINESS WIRE) - Advanced Pharmaceuticals, Inc. (OTC BB: PVCT), and a stage of development of oncology and dermatology biopharmaceutical company, announced its financial results for the year ended December 31 2007. In 2007, the company achieved a turnover of $ 0, compared to a turnover of $ 1368 and 2006. The net loss was $ 10005631 or $ 0.22 per share fully diluted, in the year 2007, compared to a net loss of $ 8870579, or $ 0.23 per share fully diluted, in the year 2006 Craig Dees, PhD, CEO of advanced, said: “We will continue our clinical studies through Phase 2 studies PV-10 for treatment of metastatic melanoma and PH-10 for the treatment of moderate to severe psoriasis, and that the results reflect our status as a development stage businesses with an acceleration of the clinic. “We are very pleased with them, as our clinical studies have so far. With regard to the PV-10, we hope that we have between the report data for the first 20 patients with melanoma in phase 2, our study shortly, and we expect D’announce the beginning of the tests to several famous places in the United States in the coming months. Our phase of the study-2 PH-10 for psoriasis continue to New York City, and we expect to announce a second phase of study launched 2 From the HEP-10 for more than one indication in the few coming months. Details of all the current studies, see the registration of clinical trials on the NIH on www.clinicaltrials.gov. “From the point of view of an enterprise, it is very important to note that we have sufficient financial resources to pursue these studies, and development of our extensive intellectual property portfolio. For example, we recently for the amount of our application for a patent in India for our officers Driving dermatology, HEP-10, and our patent applications in Europe and China, the use of the diagnosis of PV-10 and a number of useful resources for CT and MRI imaging. present, we have an international portfolio of twenty-six and four patents granted pending patents, in collaboration with the United States for the portfolio of patents granted by eighteen and four patents pending. Recently, we received a second in the amount of patent applications in the United States a novel analogue of protection photoactive PH-10. suspense The patent covers systems of medicine, PH - 12 for photodynamic therapy of cancer, skin diseases and other illnesses activation of visible light. ” He concluded: “We are very excited about the progress of our clinical trials are studies which, we are very pleased with the evolution of our intellectual property portfolio, and we are confident that we have these treatments can be made advantage to start, as soon as we received the administrative authorization. ” About Good Pharmaceuticals, Inc. (www.pvct.com) Advanced Pharmaceuticals is a biopharmaceutical company, development, specializing in oncology and dermatology treatments, safer, more efficient and less invasive and less costly than the conventional treatments. Advanced is currently in the implementation of Phase 2 clinical trials of drugs to their owners PV-10 as therapy for metastatic melanoma and PH-10 as a topical treatment of moderate to severe psoriasis. More information about these and other clinical trials, please visit the NIH Registry www.clinicaltrials.gov. The company has received Orphan Drug status by the FDA for the indication melanoma. In addition to its suite of proprietary medicines, have advanced a number of intellectual properties and technologies in the fields of imaging, medical technology and biotechnology. For additional information on Advanced, you can visit the company’s Web site or contact www.pvct.com Porter, LeVay & Rose, Inc. concerning the information found above. FORWARD LOOKING STATEMENTS: The forward-looking statements, which are included certain risks and uncertainties, which could lead actual results to differ materially from those which explains the forward-looking statements. The reader should therefore not be unduly on these forward-looking statements which relied solely on the analysis from that date. The company does not undertake to publicly revise these forward-looking statements and extend reflect events or circumstances, which are based on the date. |